Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Trump’s first-term rule—“Most Favored Nation”—was focused on lowering the cost of Medicare payments on certain drugs, but it ...

Healthcare executives are keeping a close eye on possible tariffs on foreign goods, as many supplies and drugs are wholly or partially manufactured in other countries. With supply expenses already ...

At the end of the day, the brunt of the tariffs will fall on US consumers, especially lower-income ones who rely on relatively inexpensive products from China. Now, Americans can expect longer wait ...